search
Back to results

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

Primary Purpose

Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Latuda©
Sponsored by
University of North Carolina, Chapel Hill
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia focused on measuring Latuda,lurasidone,antipsychotics,autism, mood, psychosis

Eligibility Criteria

6 Years - 19 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female children and adolescents between 6 and 19 years of age of any race or ethnicity

  • Subject must meet Diagnostic Statistical Manual (DSM)-IV-Text Revision (TR) criteria for a psychotic spectrum, mood spectrum or autism spectrum disorder as defined by one of the following diagnoses:

    • schizophrenia (any type)
    • schizoaffective disorder
    • schizophreniform disorder
    • psychosis Not Otherwise Specified (NOS)
    • autistic disorder with significant irritability/aggression (Aberrant Behavioral Checklist-Community (ABC-C) Irritability subscale score of greater than or equal to 18)
    • Asperger syndrome with significant irritability/aggression (ABC-C Irritability subscale score of greater than or equal to 18)
    • pervasive developmental disorder NOS with significant irritability/aggression (ABC-C Irritability subscale score of greater than or equal to 18)
    • bipolar type I
    • bipolar type II
    • mood disorder NOS
    • major depression with psychotic features
    • major depression (unresponsive to 2 different antidepressants)
    • severe mood dysregulation (SMD) according to Leibenluft and colleagues broad spectrum bipolar disorder
  • Subjects must have ≤ 4 weeks of lifetime exposure to an antipsychotic medication at any dosage. These medications include olanzapine (Zyprexa©), quetiapine (Seroquel©), risperidone (Risperdal©), ziprasidone (Geodon©), aripiprazole (Abilify©), asenapine (Saphris©), iloperidone (Fanapt©), lurasidone (Latuda©), haloperidol, chlorpromazine, perphenazine, fluphenazine, thiothixene, or clozapine
  • Subjects on other psychoactive medications are asked not to change dose of those medications during the course of the study unless clinically necessary
  • Sexually active girls must agree to use two effective forms of birth control (i.e. hormonal or spermicidal and barrier) or be abstinent)
  • Primary caretaker is able to participate in study appointments as is clinically indicated
  • Ability of child to participate in all aspects of the protocol per investigator's clinical judgment
  • After considering all aspects of study participation the subject (if an adult) or subject's parent or Legally Authorized Representative (LAR) must consent to participation
  • After considering all aspects of study participation, the subject must assent to participation if it is developmentally appropriate to obtain assent

Exclusion Criteria:

  • Based on current or lifetime DSM-IV-TR criteria, a diagnosis of Eating Disorder (Anorexia Nervosa or Bulimia Nervosa)
  • Based on DSM-IV-TR criteria, a diagnosis of Substance Dependence Disorder (other than tobacco dependence) within the past month
  • Treatment with the following concomitant medications: strong CYP3A4 inhibitors (ex: Ketoconazole), strong CYP3A4 inducers (ex: Rifampin)
  • Current or past treatment with lurasidone (Latuda©) that resulted in a non-response or intolerance
  • Females who are pregnant or breast-feeding
  • Ongoing or previously undisclosed child abuse requiring new department of social service intervention
  • Subjects who, in the Investigator's opinion, might not be suitable for the study

Sites / Locations

  • University of North Carolina

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Flexible Dose Latuda©

Arm Description

Lurasidone (Latuda©)dose will be determined solely by the clinician in accordance with the best interests of each participant.

Outcomes

Primary Outcome Measures

Change in Weight
Change in weight from Baseline to Week 12 will be assessed as the primary outcome measure. Subjects will be asked to step on a special scale called a tanita which will calculate weight, fat mass at each study visit.

Secondary Outcome Measures

Proportion of Participants Completing Treatment
Data will be collected on why participants terminated the study. If terminated early, the specific reason will be collected such as efficacy or tolerability.
Changes in Efficacy Measures
Efficacy measures included the Aberrant Behavior Checklist-Community (ABC-C) total score which focuses on problem behaviors in five subdomains, including irritability, attention, repetitive behaviors, unusual speech, and social withdrawal. Differences in subdomains were not assessed. The ABC-C total score is the sum of 58 items, each rated among 0 = Not at all; 1 = Slight in degree; 2 = Moderately serious; and 3 = Severe in degree. The ABC-C total score ranges from 0 to 174. Higher values of ABC-C total scores represent greater severity of illness.
Number of Participants Experiencing Side Effects
Assessment of the medication side effects associated with lurasidone (Latuda©) in children and adolescents.
Overall Clinical Improvement
Overall psychiatric functioning will be assessed with the improvement (CGI-I) subscales of the CGI. CGI-I items are rated from 1 (very much improved) to 7 (very much worse).

Full Information

First Posted
November 14, 2012
Last Updated
May 18, 2017
Sponsor
University of North Carolina, Chapel Hill
Collaborators
Foundation of Hope, North Carolina
search

1. Study Identification

Unique Protocol Identification Number
NCT01731119
Brief Title
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Official Title
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of North Carolina, Chapel Hill
Collaborators
Foundation of Hope, North Carolina

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The overarching purpose of this pilot study is to collect preliminary data regarding the variability of weight gain associated with lurasidone (Latuda©) treatment of antipsychotic naive children and adolescents in order to inform decisions about including a lurasidone arm in a future large scale trial of different approaches to minimize antipsychotic associated weight gain in the pediatric population. In adults, lurasidone appears to cause minimal weight gain. The participants will be 6-19 years old with psychotic spectrum, mood spectrum, or autism spectrum disorders. They will have 4 weeks or less of lifetime antipsychotic exposure.
Detailed Description
This is a multi-site, 12-week, open-label study assessing the weight and metabolic changes associated with lurasidone treatment. Antipsychotic (AP) naive subjects will start open-label treatment by following a flexible titration schedule. Quasi-antipsychotic naive subjects (less than 4 weeks of total AP treatment) will be started on lurasidone and tapered off the other antipsychotic over an estimated 4 weeks depending on the dose and tolerability of the prior antipsychotic. Other psychoactive medications including antidepressants, benzodiazepines, stimulants, alpha-2 agonists, and mood stabilizers are allowed as long as the dose is not changed, unless it is clinically necessary. Assessments of weight, efficacy, and side effects are conducted at baseline, week 2, week 4, week 8, and week 12. The primary outcome is percent change in weight. The secondary outcomes include psychiatric efficacy measures and side effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Keywords
Latuda,lurasidone,antipsychotics,autism, mood, psychosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Flexible Dose Latuda©
Arm Type
Experimental
Arm Description
Lurasidone (Latuda©)dose will be determined solely by the clinician in accordance with the best interests of each participant.
Intervention Type
Drug
Intervention Name(s)
Latuda©
Other Intervention Name(s)
Lurasidone Hydrochloride tablets
Intervention Description
All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
Primary Outcome Measure Information:
Title
Change in Weight
Description
Change in weight from Baseline to Week 12 will be assessed as the primary outcome measure. Subjects will be asked to step on a special scale called a tanita which will calculate weight, fat mass at each study visit.
Time Frame
Baseline to 12 weeks
Secondary Outcome Measure Information:
Title
Proportion of Participants Completing Treatment
Description
Data will be collected on why participants terminated the study. If terminated early, the specific reason will be collected such as efficacy or tolerability.
Time Frame
12 weeks
Title
Changes in Efficacy Measures
Description
Efficacy measures included the Aberrant Behavior Checklist-Community (ABC-C) total score which focuses on problem behaviors in five subdomains, including irritability, attention, repetitive behaviors, unusual speech, and social withdrawal. Differences in subdomains were not assessed. The ABC-C total score is the sum of 58 items, each rated among 0 = Not at all; 1 = Slight in degree; 2 = Moderately serious; and 3 = Severe in degree. The ABC-C total score ranges from 0 to 174. Higher values of ABC-C total scores represent greater severity of illness.
Time Frame
Baseline to 12 weeks
Title
Number of Participants Experiencing Side Effects
Description
Assessment of the medication side effects associated with lurasidone (Latuda©) in children and adolescents.
Time Frame
Baseline to12 weeks
Title
Overall Clinical Improvement
Description
Overall psychiatric functioning will be assessed with the improvement (CGI-I) subscales of the CGI. CGI-I items are rated from 1 (very much improved) to 7 (very much worse).
Time Frame
Baseline to 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female children and adolescents between 6 and 19 years of age of any race or ethnicity Subject must meet Diagnostic Statistical Manual (DSM)-IV-Text Revision (TR) criteria for a psychotic spectrum, mood spectrum or autism spectrum disorder as defined by one of the following diagnoses: schizophrenia (any type) schizoaffective disorder schizophreniform disorder psychosis Not Otherwise Specified (NOS) autistic disorder with significant irritability/aggression (Aberrant Behavioral Checklist-Community (ABC-C) Irritability subscale score of greater than or equal to 18) Asperger syndrome with significant irritability/aggression (ABC-C Irritability subscale score of greater than or equal to 18) pervasive developmental disorder NOS with significant irritability/aggression (ABC-C Irritability subscale score of greater than or equal to 18) bipolar type I bipolar type II mood disorder NOS major depression with psychotic features major depression (unresponsive to 2 different antidepressants) severe mood dysregulation (SMD) according to Leibenluft and colleagues broad spectrum bipolar disorder Subjects must have ≤ 4 weeks of lifetime exposure to an antipsychotic medication at any dosage. These medications include olanzapine (Zyprexa©), quetiapine (Seroquel©), risperidone (Risperdal©), ziprasidone (Geodon©), aripiprazole (Abilify©), asenapine (Saphris©), iloperidone (Fanapt©), lurasidone (Latuda©), haloperidol, chlorpromazine, perphenazine, fluphenazine, thiothixene, or clozapine Subjects on other psychoactive medications are asked not to change dose of those medications during the course of the study unless clinically necessary Sexually active girls must agree to use two effective forms of birth control (i.e. hormonal or spermicidal and barrier) or be abstinent) Primary caretaker is able to participate in study appointments as is clinically indicated Ability of child to participate in all aspects of the protocol per investigator's clinical judgment After considering all aspects of study participation the subject (if an adult) or subject's parent or Legally Authorized Representative (LAR) must consent to participation After considering all aspects of study participation, the subject must assent to participation if it is developmentally appropriate to obtain assent Exclusion Criteria: Based on current or lifetime DSM-IV-TR criteria, a diagnosis of Eating Disorder (Anorexia Nervosa or Bulimia Nervosa) Based on DSM-IV-TR criteria, a diagnosis of Substance Dependence Disorder (other than tobacco dependence) within the past month Treatment with the following concomitant medications: strong CYP3A4 inhibitors (ex: Ketoconazole), strong CYP3A4 inducers (ex: Rifampin) Current or past treatment with lurasidone (Latuda©) that resulted in a non-response or intolerance Females who are pregnant or breast-feeding Ongoing or previously undisclosed child abuse requiring new department of social service intervention Subjects who, in the Investigator's opinion, might not be suitable for the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Linmarie Sikich, MD
Organizational Affiliation
University of North Carolina, Chapel Hill
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of North Carolina
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27517
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

We'll reach out to this number within 24 hrs